Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Arsenic trioxide oral - Syros Pharmaceuticals

Next Previous
Drug Profile

Arsenic trioxide oral - Syros Pharmaceuticals

Alternative Names: Oral arsenic trioxide - Syros Pharmaceuticals; ORH-2014; SY-2101

Latest Information Update: 18 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orsenix
  • Developer Syros Pharmaceuticals
  • Class Anti-inflammatories; Antineoplastics; Arsenicals; Ischaemic heart disorder therapies; Oxides; Skin disorder therapies; Small molecules
  • Mechanism of Action Apoprotein stimulants; Endothelial cell modulators; Immunostimulants; Thioredoxin reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute promyelocytic leukaemia; Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Suspended Acute promyelocytic leukaemia

Most Recent Events

  • 27 Mar 2024 Syros Pharmaceuticals has patent protection for Arsenic trioxide oral in China, Australia and Taiwan
  • 03 Nov 2023 Syros Pharmaceuticals suspends a phase I trial in Acute promyelocytic leukaemia in USA (PO), due to prioritization (NCT04996030)
  • 02 Oct 2023 Suspended - Phase-II for Acute promyelocytic leukaemia (First-line therapy) in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top